Medline ® Abstract for Reference 47
of 'Principles of cancer immunotherapy'
Enhancement of antitumor immunity by CTLA-4 blockade.
Leach DR, Krummel MF, Allison JP
One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.
Cancer Research Laboratory, University of California, Berkeley, CA 94720, USA.